The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Information on Host City and Meeting HighlightsFull Access

What’s the Latest On Schizophrenia?

Published Online:https://doi.org/10.1176/pn.38.4.0065

Psychiatrists seeking cutting-edge information on “best practices” in the treatment of schizophrenia should attend the symposium “Schizophrenia: Current Guidelines, Practices, and Effectiveness Research” on Monday, May 19, at 2 p.m. in Golden Gate Hall, B-2 level, Marriott.

Chairing the symposium will be Darrel Regier, M.D., director of APA’s Office of Research, and John McIntyre, M.D., chair of APA’s Steering Committee on Practice Guidelines.

Participants will include nationally recognized experts Anthony Lehman, M.D., Jeffrey Lieberman, M.D., Mark Olfson, M.D., M.P.H., and Joyce C. West, Ph.D.

Although there are now evidence- and expert-consensus-based practice guidelines for use as clinical tools for clinicians, significant gaps remain in the research to inform treatment decisions and best practices resulting in improved treatment outcomes.

This session will provide an overview of treatment recommendations for schizophrenia from the recently revised PORT guidelines and compare them with APA’s and other major national practice guidelines and treatment protocols for schizophrenia; describe the major gaps in the current research base to guide clinical decisions; provide an overview of NIMH’s current major national research initiatives, including the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE); and present nationally representative data from the American Psychiatric Practice Research Network on currently used treatments of adults with schizophrenia and the extent to which that care is consistent with accepted treatment protocols and guidelines. ▪